Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TScan Therapeutics, Inc. (TCRX : NSDQ)

• Company Description    TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $0.79 Daily Weekly Monthly 20 Day Moving Average: 878,274 shares Shares Outstanding: 65.35 (millions) Market Capitalization: $51.89 (millions) Beta: 1.04 52 Week High: $2.57 52 Week Low: $0.79 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.48% -6.17% 12 Week -31.55% -33.43% Year To Date -20.60% -21.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 857-399-9500 fax: - hsavelle@tscan.com http://www.tscan.com

• General Corporate Information    Officers Gavin MacBeath - Chief Executive Officer and Director Jason A. Amello - Chief Financial Officer Katina Dorton - Director Gabriela Gruia - Director Barbara Klencke - Director Peer Information TScan Therapeutics, Inc. (CORR.) TScan Therapeutics, Inc. (RSPI) TScan Therapeutics, Inc. (CGXP) TScan Therapeutics, Inc. (BGEN) TScan Therapeutics, Inc. (GTBP) TScan Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89854M101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 65.35 Most Recent Split Date: (:1) Beta: 1.04 Market Capitalization: $51.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.49 Price/Cash Flow: - Price / Sales: 5.68 EPS Growth vs. Year Ago Period: 15.38% vs. Previous Quarter: -22.22% Sales Growth vs. Year Ago Period: -54.77% vs. Previous Quarter: -61.75% ROE 06/30/26 - - 03/31/26 - -91.94 12/31/25 - -79.36 ROA 06/30/26 - - 03/31/26 - -50.15 12/31/25 - -46.25 Current Ratio 06/30/26 - - 03/31/26 - 6.65 12/31/25 - 8.41 Quick Ratio 06/30/26 - - 03/31/26 - 6.65 12/31/25 - 8.41 Operating Margin 06/30/26 - - 03/31/26 - -1,360.61 12/31/25 - -1,256.81 Net Margin 06/30/26 - - 03/31/26 - -1,360.61 12/31/25 - -1,256.81 Pre-Tax Margin 06/30/26 - - 03/31/26 - -1,360.61 12/31/25 - -1,256.81 Book Value 06/30/26 - - 03/31/26 - 1.61 12/31/25 - 2.16 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.34 12/31/25 - 0.26 Debt-to-Capital 06/30/26 - - 03/31/26 - 25.20 12/31/25 - 20.90

Powered by Zacks Investment Research ©